Premium
Glucagon‐like peptide‐1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Author(s) -
Storgaard Heidi,
Cold Frederik,
Gluud Lise L.,
Vilsbøll Tina,
Knop Filip K.
Publication year - 2017
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12885
Subject(s) - medicine , placebo , type 2 diabetes , acute pancreatitis , odds ratio , adverse effect , randomized controlled trial , pancreatitis , glucagon like peptide 1 receptor , diabetes mellitus , agonist , endocrinology , receptor , alternative medicine , pathology
Glucagon‐like peptide‐1 receptor agonist ( GLP‐1RAs ) labels warn about acute pancreatitis ( AP ) and impose upon doctors the obligation to inform patients about symptoms of AP . Here we systematically reviewed the risk of AP in randomized placebo‐controlled trials ( RCTs ) investigating the effect of GLP‐1RAs in type 2 diabetes. We performed a systematic review with meta‐analysis of long‐term (minimum 24 months), placebo‐controlled GLP‐1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high‐quality RCTs included a total of 9347 GLP‐1RA ‐treated and 9353 placebo‐treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1‐RA was not associated with increased risk of AP ( P eto odds ratio 0.745 [95% CI , 0.47‐1.17]). Trial S equential A nalysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP‐1RA increases the risk of AP in patients with type 2 diabetes.